Exclusive: China FDA Review Of Multi-Regional Clinical Trials May Throw Up Domestic Roadblock
This article was originally published in PharmAsia News
Executive Summary
China FDA is conducting a review of multi-regional clinical studies by multinational drug makers, which could potentially discourage such studies in China by making the process more convoluted.